Terms: = Thyroid cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Treatment
21 results:
1. Prediction of potential mechanisms of rhubarb therapy for colorectal cancer based on network pharmacological analysis and molecular docking.
Yang F; Li X; Zhang Y; Ren Y; Zhang J; Xiao K
Medicine (Baltimore); 2024 Mar; 103(12):e37477. PubMed ID: 38518016
[TBL] [Abstract] [Full Text] [Related]
2. Combination therapy of tyrosine kinase inhibitor sorafenib with the hsp90 inhibitor onalespib as a novel treatment regimen for thyroid cancer.
Mortensen ACL; Berglund H; Hariri M; Papalanis E; Malmberg C; Spiegelberg D
Sci Rep; 2023 Oct; 13(1):16844. PubMed ID: 37803074
[TBL] [Abstract] [Full Text] [Related]
3. Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for cancer treatment - Pharmacology and Mechanisms.
Xing Z; Su A; Mi L; Zhang Y; He T; Qiu Y; Wei T; Li Z; Zhu J; Wu W
Drug Des Devel Ther; 2023; 17():2909-2929. PubMed ID: 37753228
[TBL] [Abstract] [Full Text] [Related]
4. Isoquercitrin Induces Endoplasmic Reticulum Stress and Immunogenic Cell Death in Gastric cancer Cells.
Liu J; Ren L; Wang H; Li Z
Biochem Genet; 2023 Jun; 61(3):1128-1142. PubMed ID: 36480095
[TBL] [Abstract] [Full Text] [Related]
5. Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.
Oliinyk D; Augustin T; Rauch J; Koehler VF; Belka C; Spitzweg C; Käsmann L
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3527-3547. PubMed ID: 35960373
[TBL] [Abstract] [Full Text] [Related]
6. Molecular Chaperones and thyroid cancer.
Paladino L; Vitale AM; Santonocito R; Pitruzzella A; Cipolla C; Graceffa G; Bucchieri F; Conway de Macario E; Macario AJL; Rappa F
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33919591
[TBL] [Abstract] [Full Text] [Related]
7. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
[TBL] [Abstract] [Full Text] [Related]
8. Pretherapeutic 124I dosimetry reliably predicts intratherapeutic blood kinetics of 131I in patients with differentiated thyroid carcinoma receiving high therapeutic activities.
Ruhlmann M; Sonnenschein W; Nagarajah J; Binse I; Herrmann K; Jentzen W
Nucl Med Commun; 2018 May; 39(5):457-464. PubMed ID: 29517576
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy of an hsp90 inhibitor, ganetespib, in preclinical thyroid cancer models.
Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ
Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040
[TBL] [Abstract] [Full Text] [Related]
10. hsp90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
[TBL] [Abstract] [Full Text] [Related]
11. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546
[TBL] [Abstract] [Full Text] [Related]
12. Novel hsp90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion.
White PT; Subramanian C; Zhu Q; Zhang H; Zhao H; Gallagher R; Timmermann BN; Blagg BS; Cohen MS
Surgery; 2016 Jan; 159(1):142-51. PubMed ID: 26542767
[TBL] [Abstract] [Full Text] [Related]
13. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
[TBL] [Abstract] [Full Text] [Related]
14. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract] [Full Text] [Related]
15. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Endocrine; 2015 Apr; 48(3):886-93. PubMed ID: 25096912
[TBL] [Abstract] [Full Text] [Related]
16. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract] [Full Text] [Related]
17. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
[TBL] [Abstract] [Full Text] [Related]
18. HIF-1α and hsp90: target molecules selected from a tumorigenic papillary thyroid carcinoma cell line.
Mo JH; Choi IJ; Jeong WJ; Jeon EH; Ahn SH
Cancer Sci; 2012 Mar; 103(3):464-71. PubMed ID: 22151618
[TBL] [Abstract] [Full Text] [Related]
19. Nucleotide receptors stimulation by extracellular ATP controls hsp90 expression through APE1/Ref-1 in thyroid cancer cells: a novel tumorigenic pathway.
Pines A; Bivi N; Vascotto C; Romanello M; D'Ambrosio C; Scaloni A; Damante G; Morisi R; Filetti S; Ferretti E; Quadrifoglio F; Tell G
J Cell Physiol; 2006 Oct; 209(1):44-55. PubMed ID: 16741950
[TBL] [Abstract] [Full Text] [Related]
20. The clinical applications of heat shock protein inhibitors in cancer - present and future.
Banerji U; Judson I; Workman P
Curr Cancer Drug Targets; 2003 Oct; 3(5):385-90. PubMed ID: 14529390
[TBL] [Abstract] [Full Text] [Related]
[Next]
